An unstable patient with PE who has right heart strain or elevated biomarkers is classified as which risk category and what is the initial treatment?

An unstable patient with PE who has right heart strain or elevated biomarkers is classified as which risk category and what is the initial treatment?

• A. Low risk; Anticoagulation only
• B. Intermediate risk; Anticoagulation only
• C. High risk; Reperfusion therapy plus anticoagulation
• D. High risk; Antiplatelet therapy

Answer: (C)

Unstable PE is categorized as high risk (massive) because hemodynamic instability means the heart cannot maintain adequate blood flow. When the right ventricle is under strain or biomarkers of myocardial injury are elevated, it signals that the clot burden is causing significant burden on the heart, increasing mortality risk. In this scenario, the priority is to rapidly restore pulmonary perfusion and stabilize the patient. Reperfusion therapy is indicated to quickly dissolve the clot and improve hemodynamics, typically using systemic thrombolysis. This is added to full-dose anticoagulation, which is essential in all pulmonary embolism cases to prevent further clot formation and propagation. Antiplatelet therapy alone does not address the thromboembolic process in PE. If thrombolysis is contraindicated, alternatives such as surgical or catheter-directed embolectomy may be considered, but the combination of reperfusion therapy with anticoagulation is the best approach for a high-risk, unstable patient.

Unstable PE is categorized as high risk (massive) because hemodynamic instability means the heart cannot maintain adequate blood flow. When the right ventricle is under strain or biomarkers of myocardial injury are elevated, it signals that the clot burden is causing significant burden on the heart, increasing mortality risk. In this scenario, the priority is to rapidly restore pulmonary perfusion and stabilize the patient.

Reperfusion therapy is indicated to quickly dissolve the clot and improve hemodynamics, typically using systemic thrombolysis. This is added to full-dose anticoagulation, which is essential in all pulmonary embolism cases to prevent further clot formation and propagation. Antiplatelet therapy alone does not address the thromboembolic process in PE. If thrombolysis is contraindicated, alternatives such as surgical or catheter-directed embolectomy may be considered, but the combination of reperfusion therapy with anticoagulation is the best approach for a high-risk, unstable patient.